Physician profile
Kirk Jay Levy
NPI 1023077393
$31,055.52
in general payments reported to CMS, 2019-2025
72 companies · $4,976 in 2025
The $4,976 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $1,485 · 2021: $9,262 · 2022: $3,638 · 2023: $4,992 · 2024: $5,424 · 2025: $4,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $151 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,091.38 |
| Education | $151.40 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $8,848.38 | 2020-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $3,736.43 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $1,526.33 | 2019-2025 | |
| Lundbeck LLC | $1,159.82 | 2020-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $875.32 | 2019-2025 | |
| Emd Serono, INC. | $856.59 | 2019-2024 | Mavenclad |
| Lilly USA, LLC | $827.83 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Avadel Cns Pharmaceuticals, LLC | $809.59 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $776.80 | 2020-2025 | Wakix |
| Neurocrine Biosciences, INC. | $770.83 | 2019-2025 | Ingrezza, Ongentys |
| Jazz Pharmaceuticals INC. | $755.74 | 2019-2025 | |
| Amgen INC. | $676.68 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $660.49 | 2019-2025 | Nuplazid |
| Eisai INC. | $583.71 | 2019-2025 | |
| Pfizer INC. | $567.22 | 2021-2025 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $519.00 | 2021-2025 | Zeposia |
| Csl Behring | $478.21 | 2020-2025 | Hizentra |
| Biogen, INC. | $460.58 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Inspire Medical Systems, INC. | $444.25 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $438.35 | 2023-2025 | Sunosi, Symbravo |
| Argenx US, INC. | $426.09 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $347.87 | 2022-2025 | Briviact, Nayzilam, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $270.50 | 2020-2025 | Ultomiris |
| Tg Therapeutics, INC. | $253.14 | 2023-2025 | |
| Allergan, INC. | $235.01 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $233.46 | 2023-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceuticals, INC. | $212.33 | 2021 | |
| Kyowa Kirin, INC. | $202.88 | 2023-2025 | Nourianz |
| E.R. Squibb & Sons, L.L.C. | $186.63 | 2020-2025 | Cobenfy |
| Greenwich Biosciences, INC. | $185.81 | 2019-2021 | |
| Ceribell, INC. | $160.71 | 2024 | Pocket Eeg Device |
| Janssen Pharmaceuticals, INC | $147.79 | 2021-2023 | Ponvory |
| Acorda Therapeutics, INC | $140.35 | 2019-2024 | Inbrija |
| Neurelis, INC. | $140.06 | 2021-2025 | Valtoco |
| Azurity Pharmaceuticals, INC. | $136.75 | 2023-2025 | Horizant, Horizant |
| Aucta Pharmaceuticals, INC. | $135.90 | 2024-2025 | Motpoly Xr |
| Alnylam Pharmaceuticals INC. | $135.00 | 2021-2025 | Onpattro, Amvuttra |
| Upsher-Smith Laboratories LLC | $129.90 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $104.59 | 2019-2021 | |
| Mdd US Operations, LLC | $103.84 | 2022-2024 | Xadago, Apokyn, Apokyn |
| W. L. Gore & Associates, INC. | $98.06 | 2021-2023 | Gore Cardioform Septal Occluder |
| Arbor Pharmaceuticals, INC. | $97.71 | 2021-2022 | |
| Genentech USA, INC. | $92.14 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Ipsen Biopharmaceuticals, INC | $87.68 | 2024-2025 | Dysport |
| Astrazeneca Pharmaceuticals LP | $87.28 | 2021-2025 | Wainua |
| Merz Pharmaceuticals, LLC | $84.95 | 2025 | Xeomin, Inbrija |
| Genzyme Corporation | $75.42 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.28 | 2022 | |
| Ge Healthcare | $66.68 | 2021-2025 | |
| Aquestive Therapeutics, INC. | $54.73 | 2019 | |
| Scilex Pharmaceuticals INC. | $48.25 | 2023-2024 | Ztlido |
| Catalyst Pharmaceuticals, INC. | $44.16 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $43.81 | 2019-2021 | |
| Octapharma USA, INC. | $40.91 | 2021-2022 | |
| Abbott Laboratories | $37.32 | 2019 | |
| Corium, LLC | $32.74 | 2023 | Azstarys |
| Avion Pharmaceuticals | $30.61 | 2022-2023 | Dhivy |
| Almatica Pharma LLC | $30.02 | 2021-2023 | Gralise |
| Amneal Pharmaceuticals LLC | $29.64 | 2020-2025 | Brekiya |
| Vertical Pharmaceuticals, LLC | $29.16 | 2019 | |
| Neuronetics, INC. | $26.18 | 2024 | Neurostar Tms Therapy System |
| Assertio Therapeutics, INC. | $25.75 | 2020 | |
| Vanda Pharmaceuticals INC. | $17.66 | 2025 | Ponvory |
| Boston Scientific Corporation | $17.53 | 2019 | |
| Insightec,INC | $16.89 | 2025 | Exablate |
| Life Molecular Imaging LTD | $16.88 | 2024 | Neuraceq |
| Merck Sharp & Dohme LLC | $16.39 | 2023 | Belsomra |
| Banner Life Sciences, LLC | $14.84 | 2023 | |
| Currax Pharmaceuticals LLC | $14.55 | 2020 | |
| Grifols USA, LLC | $14.39 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.21 | 2019 | |
| Tris Pharma INC | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.